EXOME

all the information, none of the junk | biotech • healthcare • life sciences

CombinatoRx Diabetes Drug Shows Promise

CombinatoRx (NASDAQ:CRXX) reports that its Type 2 diabetes treatment, a combination of bezafibrate and diflunisal, provided statistically significant reduction in blood sugar levels and other benefits in a mid-stage clinical trial. It’s a bit of good news for Cambridge, MA-based CombinatoRx after it revealed last October that its lead arthritis drug failed in a Phase II trial.